Catalog No.
Product Name
Application
Product Information
Citations
-
Drug-Linker Conjugate for ADC
DBCO-PEG4-VC-PAB-MMAE is a conjugate designed for use in antibody-drug conjugate (ADC) synthesis, incorporating a drug-linker element. The DBCO component facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules. The included MMAE moiety, a potent inhibitor of tubulin polymerization derived from dolastatin 10, exhibits significant mitotic inhibition. This reagent is ideal for advancing research in targeted cancer therapies by enabling the precise delivery of cytotoxic agents to tumor cells. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-GGFG-Dxd is a drug-linker conjugate targeting antibody-drug conjugates (ADCs) with potent antitumor activity derived from the DNA topoisomerase I inhibitor Dxd. This compound utilizes a cleavable linker, DBCO-PEG4-GGFG, which enhances selective delivery of the therapeutic agent. DBCO-PEG4-GGFG-Dxd serves as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it a valuable tool in bioconjugation applications. -
Drug-Linker Conjugate for ADC
MC-VA-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a peptide linker, MC-VA-PAB, with Exatecan, a potent inhibitor of DNA topoisomerase I, to enhance therapeutic efficacy. Synthesis of MC-VA-PAB-Exatecan-based ADCs demonstrates significant antitumor activity, making it a valuable tool for cancer research and drug development. -
Drug-Linker Conjugates for ADC
DL-01 formic is a versatile drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It facilitates the covalent attachment of cytotoxic agents to antibodies, enhancing selective targeting of cancer cells. This reagent plays a crucial role in the development and optimization of ADC formulations for targeted cancer therapies, providing a means to improve therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
PB038 is a drug-linker conjugate featuring a polyethylene glycol (PEG) unit and a cleavable linker connected to Exatecan. This compound is designed to facilitate the targeted delivery of cytotoxic agents in antibody-drug conjugates (ADCs), enhancing therapeutic efficacy while minimizing off-target effects. PB038 is suitable for research applications focused on cancer therapeutics and drug development involving ADC technology. -
Drug-Linker Conjugates for ADC
Mc-VC-PAB-SN38 is a cleavable drug-linker conjugate that combines a linker (Mc-VC-PAB) with the potent DNA topoisomerase I inhibitor SN38. This compound is designed for the synthesis of antibody-drug conjugates (ADCs), providing a targeted approach for delivering therapeutic agents to malignant cells. Its unique structure facilitates the release of SN38 within the cellular environment, enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
MC-betaglucuronide-MMAE-1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound exhibits potent antitumor activity through the action of MMAE, a tubulin polymerization inhibitor. The incorporation of the cleavable ADC linker MC-betaglucuronide enables targeted delivery and release of MMAE in tumor cells, enhancing therapeutic efficacy in cancer research. -
Drug-Linker Conjugate For ADC
MC-VA-PABC-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound integrates the linker peptide MC-VA-PABC with the potent tubulin polymerization inhibitor MMAE, facilitating targeted delivery of the cytotoxic agent. It plays a crucial role in enhancing the therapeutic efficacy of ADCs in cancer research by selectively delivering MMAE to tumor cells while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the ADC linker Gly-Mal-GGFG with the cytotoxic agent Deruxtecan 2-hydroxypropanamide, facilitating targeted delivery of therapeutic agents to cancer cells. It is primarily utilized in research focused on improving the efficacy and specificity of cancer therapies. -
Drug-Linker Conjugates for ADC
AZ14170133 is a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound comprises a cytotoxic payload, a topoisomerase 1 inhibitor, linked for effective targeted delivery. AZ14170133 is utilized in the synthesis of ADCs such as AZD9592 and AZD8205, making it a valuable tool for cancer research focused on developing innovative therapeutic strategies. -
Drug-Linker Conjugates for ADC
Gly3-VC-PAB-MMAE is a cleavable drug-linker conjugate comprising the linker Gly3-VC-PAB and the potent tubulin inhibitor MMAE. This compound facilitates the synthesis of antibody-drug conjugates (ADCs) by enabling targeted delivery of MMAE to cancer cells. Its unique structure allows for the selective release of the cytotoxic agent in the tumor microenvironment, making it valuable in cancer research and therapeutic development. -
Drug-Linker Conjugate for ADC
Mal-VC-PAB-DM1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features DM1, a potent microtubule-disrupting agent, linked by the Mal-VC-PAB linker, which enhances targeted delivery to tumor cells. Mal-VC-PAB-DM1 exhibits significant antitumor activity, making it a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-Val-Cit-PAB-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) that combines a cleavable PEG linker with the potent tubulin polymerization inhibitor MMAF. The DBCO moiety facilitates efficient synthesis through click chemistry, specifically strain-promoted alkyne-azide cycloaddition (SPAAC), allowing for precise conjugation to azide-containing biomolecules. This reagent is essential for enhancing the therapeutic efficacy of ADCs by enabling targeted delivery of cytotoxic agents. -
Anti-Nectin-4 ADC Linker
Mal-PEG8-Val-Ala-PAB-Exatecan is an anti-Nectin-4 antibody-drug conjugate (ADC) linker designed to facilitate targeted delivery of chemotherapeutic agents. This compound enables precise conjugation to Nectin-4 polypeptides, allowing for enhanced therapeutic efficacy in cancer research applications. Its unique structure promotes stability and release characteristics, making it suitable for studying the effects of ADCs in various tumor models. -
Drug-linker Conjugate for ADC
NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features a cleavable linker, NH2-PEG3-VC-PAB, which is linked to the potent tubulin inhibitor Monomethyl auristatin E (MMAE). This reagent is essential for facilitating targeted delivery and localized cytotoxicity in cancer research and therapeutic applications. -
Drug-Linker Conjugates for ADC
Mal-PEG8-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker that facilitates selective release of the potent tubulin inhibitor MMAE upon internalization by target cells. It is ideal for research aimed at improving the therapeutic index of ADCs through targeted delivery and enhanced cytotoxicity against cancer cells. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-MMAF is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, utilizing MMAF as a potent tubulin polymerization inhibitor. The conjugate features a cleavable linker, DBCO-PEG4, which facilitates the selective release of MMAF within target cells. DBCO-PEG4-MMAF serves as a click chemistry reagent, containing a DBCO group that efficiently engages in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-modified molecules, making it a valuable tool for targeted therapeutics in cancer research. -
Drug-Linker Conjugate for ADC
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, targeting microtubules to exert potent antitumor effects. The compound features the anti-microtubule agent Eribulin, which is covalently linked via the Mal-(CH2)5-Val-Cit-PAB linker. This strategic design enhances the therapeutic efficacy of Eribulin while minimizing systemic toxicity, making it a valuable tool for cancer research and development. -
Drug-Linker Conjugate for ADC
MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features Exatecan, a potent inhibitor of DNA Topoisomerase I with an IC50 of 2.2 μM, which interferes with DNA replication and induces apoptosis in cancer cells. Its application in ADCs allows for targeted delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
DBCO-(PEG2-VC-PAB-MMAE)2 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, linked to a cleavable DBCO-(PEG2-VC-PAB)2 linker. The DBCO group enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, facilitating targeted delivery of cytotoxic agents. Its application is crucial for research in cancer therapeutics, particularly in enhancing the efficacy and selectivity of ADCs. -
ADC Linker
SuO-Glu-Val-Cit-PAB-MMAE is a cleavable antibody-drug conjugate (ADC) linker that combines SuO-Glu-Val-Cit-PAB with the potent tubulin inhibitor MMAE. This compound enables targeted delivery of MMAE via ADC technology, facilitating selective cytotoxicity in cancer research. SuO-Glu-Val-Cit-PAB-MMAE is suitable for the synthesis of ADCs, providing a strategic approach to enhance therapeutic efficacy while minimizing off-target effects. -
Cleavable ADC Linker
Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates selective drug delivery by connecting antibodies to the cytotoxic agent MMAE, enhancing therapeutic efficacy while minimizing off-target effects. Its PEG4 moiety ensures improved solubility and stability, making it suitable for research applications in cancer therapy and targeted delivery systems. -
Drug-Linker Conjugates for ADC
Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the ADC linker Mal-PEG4-VC-PAB with the cytotoxic agent DMEA-PNU-159682, which derives from metabolites of nemorubicin (MMDX) processed by liver microsomes. It exhibits strong cytotoxicity, making it suitable for targeted cancer therapies in research focused on ADC development and optimization. -
Drug-Linker Conjugates for ADC
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. The linker comprises Gly-Gly-Phe-Gly-NH-O-CO, which is attached to Exatecan, a potent inhibitor of DNA topoisomerase I. This compound exhibits significant potential in cancer research, facilitating targeted delivery and enhanced therapeutic efficacy in anticancer treatments. -
Drug-Linker Conjugates for ADC
Doxorubicin-SMCC is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), featuring a non-cleavable linker and the anthracycline antibiotic Doxorubicin. Doxorubicin targets DNA topoisomerase II, interrupting DNA replication and transcription processes, which leads to cell death in rapidly dividing cancer cells. This reagent is valuable for research applications focused on targeted cancer therapies and the development of innovative drug delivery systems. -
Drug-Linker Conjugate For ADC
TCO-PEG4-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker (TCO-PEG4-VC-PA) that facilitates the release of the potent tubulin inhibitor MMAE upon cellular internalization. TCO-PEG4-VC-PAB-MMAE incorporates a TCO group suitable for inverse electron demand Diels-Alder (iEDDA) reactions, enabling highly specific conjugation with tetrazine-containing molecules, thus enhancing therapeutic efficacy in targeted treatments. -
Drug-Linker Conjugates for ADC
MC-EVCit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features the MC-EVCit-PAB linker combined with the potent tubulin polymerization inhibitor MMAE, which contributes to its cytotoxic properties. MC-EVCit-PAB-MMAE is utilized in research applications focused on targeted cancer therapies, enhancing the efficacy of ADCs through selective delivery of the chemotherapeutic agent. -
Drug-Linker Conjugates for ADC
MC-SN38 is a drug-linker conjugate that combines the potent microtubule-disrupting agent SN38 with a non-cleavable MC linker, designed for the development of antibody-drug conjugates (ADCs). SN38, a bioactive metabolite of the Topoisomerase I inhibitor Irinotecan, exerts its biological activity by inhibiting DNA synthesis and inducing DNA single-strand breaks. This compound is essential for research into targeted cancer therapies that leverage the specificity of antibodies to deliver cytotoxic agents to tumor cells. -
Drug-Linker Conjugate for ADC
SGD-1910 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It utilizes the antitumor antibiotic pyrrolobenzodiazepine (PBD), known for its cytotoxic DNA crosslinking activity, linked through the cleavable peptide MC-Val-Ala. This compound demonstrates significant potential in targeted cancer therapies by allowing for the precise delivery of cytotoxic agents, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
DBCO-(PEG)3-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features Monomethyl auristatin E (MMAE) linked to a DBCO-(PEG)3-VC-PAB structure, facilitating targeted drug delivery in cancer research. As a click chemistry reagent, it utilizes a DBCO group that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it valuable in bioconjugation applications. -
Drug-Linker Conjugate for ADC
DBCO-PEG3-VC-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the DBCO-PEG3-VC linker with Exatecan, a potent inhibitor of DNA topoisomerase I. Its structure facilitates targeted delivery of the cytotoxic agent to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. Research applications include the development of ADCs for cancer treatment, providing a strategic tool for targeted therapy and molecular oncology studies. -
Drug-Linker Conjugate for ADC
SC-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This molecule features the potent antitumor agent monomethyl auristatin E (MMAE), a tubulin inhibitor that disrupts microtubule dynamics, linked through a cleavable SC-VC-PAB linker. SC-VC-PAB-MMAE demonstrates effective cytotoxicity in targeted cancer therapies, making it a valuable tool for research in oncology and ADC development. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-VA-PBD is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound utilizes the potent antitumor antibiotic Pyrrolobenzodiazepine (PBD), which is linked via a DBCO-PEG4-VA spacer. DBCO-PEG4-VA-PBD acts as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. This functionality supports the development of targeted therapies for cancer treatment, enhancing the efficacy of ADCs. -
Drug-Linker Conjugates for ADC
endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable linker specifically designed for antibody-drug conjugates (ADCs), facilitating the targeted delivery of therapeutic agents. This compound features a 4-unit polyethylene glycol (PEG) chain and incorporates a BCN group that enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its versatility is highly applicable in the development of ADCs, enhancing the efficacy and specificity of cancer therapies. -
Drug-Linker Conjugate for ADC
Val-Ala-PABC-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a cleavable Tesirine linker (Val-Ala-PABC) coupled with Exatecan, a potent topoisomerase I inhibitor. This conjugate facilitates targeted delivery of cytotoxic agents, making it suitable for the synthesis of various ADC molecules, such as Mal-PEGn-amide-va-Exatecan. Its ability to selectively release the active drug upon internalization enhances therapeutic efficacy against cancer cells. -
Drug-Linker Conjugates for ADC
Val-Ala-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs), comprising the valine-alanine-PAB linker and the cytotoxic agent MMAE. MMAE acts primarily as a potent inhibitor of tubulin, disrupting microtubule dynamics and effectively inducing apoptosis in cancer cells. This reagent is utilized in the development and characterization of ADCs for targeted cancer therapies, enhancing specificity and reducing systemic exposure. -
Drug-Linker Conjugate for ADC
DM21 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features a maytansinoid microtubule-disrupting payload linked through a stable tripeptide linker, enhancing its therapeutic efficacy. DM21 is conjugated with a humanized antibody targeting ADAM9, resulting in the formulation of IMGC936, which holds promise in cancer research and targeted therapies. -
Drug-Linker Conjugate for ADC
Mal-PEG4-VA-PBD is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It utilizes the potent antitumor antibiotic Pyrrolobenzodiazepine (PBD), which is covalently linked through Mal-PEG4-VA. This compound facilitates targeted delivery of PBD to tumor cells, enhancing therapeutic efficacy while minimizing off-target effects. Mal-PEG4-VA-PBD is ideal for research into ADC development and optimization in cancer therapy. -
Drug-Linker Conjugates for ADC
TL033 TFA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a linker that connects bioactive small molecule toxins, facilitating targeted delivery of cytotoxic agents. When conjugated with the Sacituzumab antibody (anti-Trop-2), TL033 TFA enables the synthesis of BT001021, which demonstrates potent anti-cancer activity across various malignancies, including breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer. -
Drug-Linker Conjugates for ADC
Py-MAA-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent cytotoxic agent MMAE. This compound facilitates the synthesis of Zapadcine-3a, which selectively targets TRAILR2. Zapadcine-3a exhibits broad-spectrum anti-tumor activity, effectively inducing apoptosis in TRAILR2-positive tumors. This makes Py-MAA-Val-Cit-PAB-MMAE a valuable tool for advancing targeted cancer therapeutics. -
Drug-Linker Conjugate for ADC
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br functions as a drug-linker conjugate for antibody-drug conjugate (ADC) applications. This compound facilitates the synthesis of various therapeutic agents, including ABBV-154, ABBV-927, and ABBV-368, by effectively targeting the glucocorticoid receptor. Its utility in ADC development makes it a valuable reagent for researchers focused on innovative treatment strategies in oncology and immunology. -
Drug-Linker Conjugate for ADC
Amino-PEG4-GGFG-Dxd is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features Dxd as the active drug component linked via a PEG4 spacer, facilitating effective conjugation to antibodies. Amino-PEG4-GGFG-Dxd is suitable for the synthesis of ADCs, providing a versatile tool for targeted cancer therapy research. -
Drug-Linker Conjugate for ADC
MMAE-SMCC is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It consists of the potent mitotic inhibitor Monomethyl Auristatin E (MMAE) conjugated through a stable SMCC linker. This compound targets microtubule dynamics, effectively inhibiting cell division in cancer cells. MMAE-SMCC serves as a valuable tool in the development of targeted cancer therapies, allowing for selective delivery of cytotoxic agents to tumor cells. -
Drug-Linker Conjugates for ADC
Propargyl-PEG4-GGFG-DXd is a drug-linker conjugate specifically designed for antibody-drug conjugate (ADC) applications. This compound includes a PEG-based linker that facilitates the delivery of the DNA topoisomerase I inhibitor DXd. Propargyl-PEG4-GGFG-DXd is utilized in research for targeted cancer therapy, enabling precise drug delivery to tumor cells while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
Val-Cit-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a DNA topoisomerase I inhibitor, DX-8951, linked via a cathepsin-cleavable linker, Val-Cit-PAB. Its primary mechanism involves targeted delivery of the cytotoxic agent to cancer cells, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. Val-Cit-PAB-Exatecan is utilized in research focused on developing effective ADC therapies for various malignancies. -
Drug-Linker Conjugate for ADC
MC-GGFG-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates the selective delivery of cytotoxic agents to targeted cells, enhancing therapeutic efficacy while minimizing off-target effects. It is instrumental in the development of ADCs for cancer treatment research and other therapeutic applications. -
Drug-Linker Conjugates for ADC
SN38-COOH is a key component for the synthesis of antibody-drug conjugates (ADCs). It serves as a functionalized form of SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, which effectively inhibits DNA and RNA synthesis in target cells. This compound is utilized in research focused on targeted cancer therapies, allowing for the precise delivery of cytotoxic agents to improve therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the cytotoxic agent Exatecan with a specialized linker, enabling targeted delivery to cancer cells. Mal-Val-Ala-PAB-N(SO2Me)-Exatecan is utilized in the synthesis of FZ-AD005, an ADC targeting delta-like ligand 3 (DLL3) with a binding affinity of 58.3 pM, which demonstrates significant antitumor activity against small cell lung cancer (SCLC). -
Drug-Linker Conjugate for ADC
DBM-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), featuring the potent antitubulin agent MMAF combined with the DBM linker. This compound exerts significant cytotoxic activity through microtubule disruption, facilitating targeted delivery of therapeutic agents to cancer cells. DBM-MMAF is utilized in research applications focused on ADC development and the study of targeted cancer therapies. -
Drug-Linker Conjugate for ADC
DBM-C5-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It consists of a C5-VC-PAB linker coupled with a maleimide functional group and the potent cytotoxic agent MMAE. This conjugate is utilized in targeted cancer therapies, enhancing the selective delivery of MMAE to tumor cells while minimizing systemic exposure. Its unique structural components facilitate effective conjugation to antibodies, paving the way for innovative approaches in oncology research.
